Device Trial Radar · NCT04816604
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
74
Actual
Start
Apr 5, 2021
Primary completion
Sep 9, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Gossamer Bio USA, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Conditions
- Pulmonary Arterial Hypertension
Interventions
GB002 (seralutinib)Drug
Capsule containing GB002 (seralutinib)
Generic Dry Powder InhalerDevice
Generic dry powder inhaler for GB002 (seralutinib) delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse EventsTime frame: From first dose of study drug up to 80 months or availability of commercial product
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
University of California, Davis Medical Center
Sacramento, California
Medical Corporation
Santa Barbara, California
Mayo Clinic
Jacksonville, Florida
25 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.